The clinical applications of human gene therapy have been particularly fruitful in oncology, and in the past two decades there has been explosive growth in understanding of the genetic lesions leading to neoplasia. This volume in the series Cancer: Clinical Science in Practice reviews progress in the basic and clinical science of gene therapy in oncology, and looks toward future developments. It considers what has worked and what has not in the fast-evolving field of gene therapy, drawing on laboratory studies and clinical trials, including the ground-breaking work of the contributors...

This volume examines the current state and future prospects of cell therapy. The coverage is broad, including the scientific principles of hematopoietic cell therapy, the technology of cell collection and preparation, current and likely future clinical applications of cell therapy (including treatment of AIDS), and the principles and practice of cellular immunotherapy.

This 2006 book examines the interaction of economics and the delivery of cancer care in the global context. It analyses the causes of tension between those paying for care, those providing the care and those marketing drugs and devices. The concept and requirement for rationing is examined in different economic environments. As cancer increases in incidence and prevalence, the economics of providing care becomes a more important subject than ever before. Written by a leading health economist and oncologist, this was the first comprehensive book on the economics of cancer care continues to be...

This volume reviews advances in the field of human tumor immunology, particularly in relation to the potential for immune intervention in preventing or treating tumors. The editors and contributors, all leading workers in the field, survey advances in the understanding of the relationship between the cancer cell and the immune response. Chapters review in depth the function of immune surveillance and mechanisms of tumor immunity, the role of T lymphocytes and oncogenes in the immune response to cancer, and the potential for immunotherapy of cancer. New areas of tumor immunology are presented,...

This 2006 book examines the interaction of economics and the delivery of cancer care in the global context. It analyses the causes of tension between those paying for care, those providing the care and those marketing drugs and devices. The concept and requirement for rationing is examined in different economic environments. As cancer increases in incidence and prevalence, the economics of providing care becomes a more important subject than ever before. Written by a leading health economist and oncologist, this was the first comprehensive book on the economics of cancer care continues to be...

Interferon was first discovered in 1957. Over the last five years it has become almost a household word. Many believe it to be a drug with already proven efficacy against cancer and viral infection. The media has distorted any cool scientific view of the data available. We have learned much about the complexity of the interferon system. We know some of the switches involved in interferon gene expression and its secretion by virally and immune stimulated cells. We also know that it binds to a cell surface receptor, mediating its complex effects on target cells by a series of second messengers....